<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:05:18Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5480084" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5480084</identifier><datestamp>2017-06-23</datestamp><setSpec>cas</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id>
      <journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id>
      <journal-id journal-id-type="publisher-id">CAS</journal-id>
      <journal-title-group>
        <journal-title>Cancer Science</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1347-9032</issn>
      <issn pub-type="epub">1349-7006</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5480084</article-id>
      <article-id pub-id-type="pmcid">PMC5480084</article-id>
      <article-id pub-id-type="pmc-uid">5480084</article-id>
      <article-id pub-id-type="pmid">28294470</article-id>
      <article-id pub-id-type="doi">10.1111/cas.13233</article-id>
      <article-id pub-id-type="publisher-id">CAS13233</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Original Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
          <subj-group subj-group-type="heading">
            <subject>Genetics, Genomics, and Proteomics</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Exome sequencing deciphers a germline <italic><styled-content style="fixed-case">MET</styled-content></italic> mutation in familial epidermal growth factor receptorâmutant lung cancer</article-title>
        <alt-title alt-title-type="left-running-head">Tode <italic>et al</italic>.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="cas13233-cr-0001" contrib-type="author">
          <name>
            <surname>Tode</surname>
            <given-names>Naoki</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0002" contrib-type="author" corresp="yes">
          <name>
            <surname>Kikuchi</surname>
            <given-names>Toshiaki</given-names>
          </name>
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7428-1245</contrib-id>
          <address>
            <email>kikuchi@med.niigata-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="cas13233-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0003" contrib-type="author">
          <name>
            <surname>Sakakibara</surname>
            <given-names>Tomohiro</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0004" contrib-type="author">
          <name>
            <surname>Hirano</surname>
            <given-names>Taizou</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0005" contrib-type="author">
          <name>
            <surname>Inoue</surname>
            <given-names>Akira</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0006" contrib-type="author">
          <name>
            <surname>Ohkouchi</surname>
            <given-names>Shinya</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0007" contrib-type="author">
          <name>
            <surname>Tamada</surname>
            <given-names>Tsutomu</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0008" contrib-type="author">
          <name>
            <surname>Okazaki</surname>
            <given-names>Tatsuma</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0009" contrib-type="author">
          <name>
            <surname>Koarai</surname>
            <given-names>Akira</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0010" contrib-type="author">
          <name>
            <surname>Sugiura</surname>
            <given-names>Hisatoshi</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0011" contrib-type="author">
          <name>
            <surname>Niihori</surname>
            <given-names>Tetsuya</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0012" contrib-type="author">
          <name>
            <surname>Aoki</surname>
            <given-names>Yoko</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0013" contrib-type="author">
          <name>
            <surname>Nakayama</surname>
            <given-names>Keiko</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0014" contrib-type="author">
          <name>
            <surname>Matsumoto</surname>
            <given-names>Kunio</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0015" contrib-type="author">
          <name>
            <surname>Matsubara</surname>
            <given-names>Yoichi</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0004">
<sup>4</sup>
</xref>
          <xref ref-type="aff" rid="cas13233-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0016" contrib-type="author">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Masayuki</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0008">
<sup>8</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0017" contrib-type="author">
          <name>
            <surname>Watanabe</surname>
            <given-names>Akira</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0009">
<sup>9</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0018" contrib-type="author">
          <name>
            <surname>Nukiwa</surname>
            <given-names>Toshihiro</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="cas13233-cr-0019" contrib-type="author">
          <name>
            <surname>Ichinose</surname>
            <given-names>Masakazu</given-names>
          </name>
          <xref ref-type="aff" rid="cas13233-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="cas13233-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Respiratory Medicine</named-content>
        <institution>Tohoku University Graduate School of Medicine</institution>
        <named-content content-type="city">Sendai</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Department of Respiratory Medicine and Infectious Diseases</named-content>
        <institution>Niigata University Graduate School of Medical and Dental Sciences</institution>
        <named-content content-type="city">Niigata</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Palliative Medicine</named-content>
        <institution>Tohoku University Graduate School of Medicine</institution>
        <named-content content-type="city">Sendai</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medical Genetics</named-content>
        <institution>Tohoku University Graduate School of Medicine</institution>
        <named-content content-type="city">Sendai</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <named-content content-type="organisation-division">Division of Cell Proliferation</named-content>
        <institution>United Centers for Advanced Research and Translational Medicine</institution>
        <institution>Tohoku University Graduate School of Medicine</institution>
        <named-content content-type="city">Sendai</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0006">
        <label>
          <sup>6</sup>
        </label>
        <named-content content-type="organisation-division">Division of Tumor Dynamics and Regulation</named-content>
        <named-content content-type="organisation-division">Cancer Research Institute</named-content>
        <institution>Kanazawa University</institution>
        <named-content content-type="city">Kanazawa</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0007">
        <label>
          <sup>7</sup>
        </label>
        <institution>National Center for Child Health and Development</institution>
        <named-content content-type="city">Tokyo</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0008">
        <label>
          <sup>8</sup>
        </label>
        <named-content content-type="organisation-division">Department of Medical Biochemistry</named-content>
        <institution>Tohoku University Graduate School of Medicine</institution>
        <named-content content-type="city">Sendai</named-content>
        <country country="JP">Japan</country>
      </aff>
      <aff id="cas13233-aff-0009">
        <label>
          <sup>9</sup>
        </label>
        <named-content content-type="organisation-division">Research Division for Development of AntiâInfective Agents</named-content>
        <named-content content-type="organisation-division">Institute of Development, Aging and Cancer</named-content>
        <institution>Tohoku University</institution>
        <named-content content-type="city">Sendai</named-content>
        <country country="JP">Japan</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Toshiaki Kikuchi, Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 1â757 Asahimachidori, Chuoku, Niigata 951â8510, Japan.<break/>
Tel: +81 25 368 9321; Fax: +81 25 368 9326;<break/>
Eâmail: <email>kikuchi@med.niigata-u.ac.jp</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>5</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2017</year>
      </pub-date>
      <volume>108</volume>
      <issue>6</issue>
      <issue-id pub-id-type="doi">10.1111/cas.2017.108.issue-6</issue-id>
      <fpage>1263</fpage>
      <lpage>1270</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>12</month>
          <year>2016</year>
        </date>
        <date date-type="rev-recd">
          <day>22</day>
          <month>2</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>3</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Japanese Cancer Association <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2017 The Authors. <italic>Cancer Science</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement>
        <license license-type="creativeCommonsBy-nc">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons AttributionâNonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-108-1263.pdf"/>
      <abstract id="cas13233-abs-0001">
        <p>Lung cancer accompanied by somatic activating mutations in the epidermal growth factor receptor (<italic><styled-content style="fixed-case">EGFR</styled-content></italic>) gene, which is associated with a significant clinical response to the targeted therapy, is frequently found in neverâsmoking Asian women with adenocarcinoma. Although this implies genetic factors underlying the carcinogenesis, the etiology remains unclear. To gain insight into the pathogenic mechanisms, we sequenced the exomes in the peripheralâblood <styled-content style="fixed-case">DNA</styled-content> from six siblings, four affected and two unaffected siblings, of a family with familial <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung adenocarcinoma. We identified a heterozygous missense mutation in <italic><styled-content style="fixed-case">MET</styled-content></italic> protoâoncogene, p.Asn375Lys, in all four affected siblings. Combined with somatic loss of heterozygosity for <italic><styled-content style="fixed-case">MET</styled-content></italic>, the higher allele frequency in a Japanese sequencing database supports a causative role of the <italic><styled-content style="fixed-case">MET</styled-content></italic> mutation in <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer. Functional assays showed that the mutation reduces the binding affinity of <styled-content style="fixed-case">MET</styled-content> for its ligand, hepatocyte growth factor, and damages the subsequent cellular processes, including proliferation, clonogenicity, motility and tumorigenicity. The <italic><styled-content style="fixed-case">MET</styled-content></italic> mutation was further observed to abrogate the <styled-content style="fixed-case">ERBB</styled-content>3âmediated <styled-content style="fixed-case">AKT</styled-content> signal transduction, which is shared downstream by <styled-content style="fixed-case">EGFR</styled-content>. These findings provide an etiological view that the <italic><styled-content style="fixed-case">MET</styled-content></italic> mutation is involved in the pathogenesis of <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer because it generates oncogenic stress that induces compensatory <styled-content style="fixed-case">EGFR</styled-content> activation. The identification of <italic><styled-content style="fixed-case">MET</styled-content></italic> in a family with familial <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer is insightful to explore the pathogenic mechanism of not only familial, but also sporadic <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer by underscoring <styled-content style="fixed-case">MET</styled-content>ârelated signaling molecules.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="cas13233-kwd-0001">Epidermal growth factor receptor</kwd>
        <kwd id="cas13233-kwd-0002">exome</kwd>
        <kwd id="cas13233-kwd-0003">familial lung cancer</kwd>
        <kwd id="cas13233-kwd-0004">human <styled-content style="fixed-case">MET</styled-content> protein</kwd>
        <kwd id="cas13233-kwd-0005">missense mutation</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Ministry of Education, Culture, Sports, Science and Technology (Tokyo, Japan)</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Japan Science and Technology Agency (Tokyo, Japan)</funding-source>
        </award-group>
      </funding-group>
      <funding-group>
        <award-group>
          <funding-source>Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan)</funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="5"/>
        <table-count count="0"/>
        <page-count count="8"/>
        <word-count count="5777"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>cas13233</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>June 2017</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.1 mode:remove_FC converted:22.06.2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="cas13233-cit-1001">
<source>Cancer Sci</source>
<volume>108</volume> (<year>2017</year>) <fpage>1263</fpage>â<lpage>1270</lpage>
</mixed-citation>
</p>
    </notes>
    <notes>
      <fn-group id="cas13233-ntgp-0001">
        <fn fn-type="funding" id="cas13233-note-1001">
          <p>
<bold>Funding Information</bold>
</p>
          <p>This work was supported, in part, by GrantsâinâAid for Scientific Research and the Project for Development of Innovative Research on Cancer Therapeutics from the Ministry of Education, Culture, Sports, Science and Technology (Tokyo, Japan), the Core Research for Evolutional Science and Technology Program, the Adaptable and Seamless Technology Transfer Program from the Japan Science and Technology Agency (Tokyo, Japan), and the Urgent Research Grant Program from the Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan).</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <p>Lung cancer is the leading cause of cancer death worldwide, with the estimated number of annual deaths around 1.4 million.<xref rid="cas13233-bib-0001" ref-type="ref">1</xref>, <xref rid="cas13233-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13233-bib-0003" ref-type="ref">3</xref> Cigarette smoking is a predominant etiological factor of lung carcinogenesis, especially for small cell lung cancer and squamous cell lung cancer.<xref rid="cas13233-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13233-bib-0004" ref-type="ref">4</xref> Increasing attention is being paid to a growing number of lung carcinomas occurring in neverâsmokers, which are estimated to account for approximately 25% of lung cancers worldwide.<xref rid="cas13233-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13233-bib-0005" ref-type="ref">5</xref> Such lung cancers in neverâsmokers are more likely to have oncogenic mutations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), which can be precisely targeted for killing the tumor cells by small molecular inhibitors of the internal tyrosine kinase.<xref rid="cas13233-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13233-bib-0005" ref-type="ref">5</xref> EGFR is of significant interest because the mutations occur more frequently in adenocarcinomas of East Asian women with a history of never smoking, suggesting that the <italic>EGFR</italic>âmutant tumor is a biologically distinct disease with a genetic susceptibility.<xref rid="cas13233-bib-0005" ref-type="ref">5</xref> Despite these insights from epidemiological evidence, the genetic etiology of <italic>EGFR</italic>âmutant lung cancer remains unknown.</p>
    <p>Epidermal growth factor receptor is a member of the vâerbâb2 erythroblastic leukemia viral oncogene (ERBB) family, commonly referred to as the human epidermal growth factor (HER) family, and is also designated as ERBB1 or HER1.<xref rid="cas13233-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13233-bib-0006" ref-type="ref">6</xref> EGFR and its family members serve as receptor tyrosine kinases and contribute to carcinogenesis through MAPâkinase and PI3âkinase (PI3K) signaling pathways that modulate cell proliferation and cell survival, respectively.<xref rid="cas13233-bib-0007" ref-type="ref">7</xref> The PI3K pathway is particularly important in lung cancer as a major signaling pathway downstream of EGFR, which confers multiple PI3Kâbinding sites by heterodimerization with ERBB3.<xref rid="cas13233-bib-0008" ref-type="ref">8</xref> In this regard, amplification of <italic>MET</italic>, coding another receptor tyrosine kinase, clinically yields acquired resistance to EGFRâtargeted therapy by forming the METâERBB3 complex to reinstate the PI3K signaling diminished by the targeted therapy for somatic activating mutations in <italic>EGFR</italic>.<xref rid="cas13233-bib-0008" ref-type="ref">8</xref>, <xref rid="cas13233-bib-0009" ref-type="ref">9</xref>
</p>
    <p>In the present study, we identified a germline mutation in <italic>MET</italic> by exome sequencing of wholeâblood DNA from a pedigree consisting of â¥3 family members affected by <italic>EGFR</italic>âmutant lung adenocarcinomas. All lung cancer patients, but not the unaffected siblings, carried the missense <italic>MET</italic> mutation that damages the biological function via impaired binding to the ligand, hepatocyte growth factor (HGF). Notably, the functional consequence of the <italic>MET</italic> mutation is an attenuation of the ERBB3âPI3K pathway in lung cancer cells, thereby potentially activating the EGFRâERBB3âPI3K signaling axis as an oncogenic stress to <italic>EGFR</italic>âmutant lung cancer.</p>
    <sec id="cas13233-sec-0002">
      <title>Materials and Methods</title>
      <sec id="cas13233-sec-0003">
        <title>Exome capture and sequencing</title>
        <p>Blood samples for DNA extraction were collected according to the protocol approved by the Institutional Review Board at Tohoku University Graduate School of Medicine (Sendai, Japan).</p>
        <p>Exome capture was performed with the SureSelect Human All Exon V4 (Agilent Technologies, Santa Clara, CA, USA). Exome capture libraries were sequenced by HiSeq 2000 (Illumina, San Diego, CA, USA) to obtain at least 83 million pairedâend (2 Ã 101 base pairs) reads per sample. A targeted mean coverage depth of 106â198 Ã with 74â91% of bases covered at â¥50 Ã was achieved for 51 Mb exome libraries (Table <xref rid="cas13233-sup-0001" ref-type="supplementary-material">S1</xref>). Additional detail on the method is provided in Supplementary Document <xref rid="cas13233-sup-0001" ref-type="supplementary-material">S1</xref>).</p>
      </sec>
      <sec id="cas13233-sec-0004">
        <title>Statistical analysis</title>
        <p>Two data sets were compared using Student's unpaired twoâtailed <italic>t</italic>âtest. For multiple comparisons, post hoc analysis was performed by Tukey's honestly significant difference test. <italic>P</italic>âvalues less than 0.05 were considered statistically significant. Error bars in the graphical data represent the means Â± standard error.</p>
      </sec>
    </sec>
    <sec id="cas13233-sec-0005">
      <title>Results</title>
      <sec id="cas13233-sec-0006">
        <title>Germline variants in a family with <italic>EGFR</italic>âmutant lung cancer</title>
        <p>We previously reported a Japanese family in which three siblings (subjects 2, 5 and 6 in Fig. <xref rid="cas13233-fig-0001" ref-type="fig">1</xref>a) were affected by lung adenocarcinoma with <italic>EGFR</italic> mutations.<xref rid="cas13233-bib-0010" ref-type="ref">10</xref> The inconsistent <italic>EGFR</italic> mutation pattern in the three siblings (subjects 2 and 5, a point mutation L858R on exon 21; subject 4, an inâframe deletion of exon 19) suggested that their genetic bases contained a vulnerability for <italic>EGFR</italic>âmutant lung cancer. After the report was published, another sibling within the family (subject 1), an 80âyearâold woman who never smoked, came to Tohoku University Hospital (Sendai, Japan) for bulbar paralysis. Given the imaging examination and her family history, she was clinically diagnosed with (probably <italic>EGFR</italic>âmutant) lung cancer and brain metastasis, although no pathologic diagnosis was achieved because of her extremely poor general condition (Fig. <xref rid="cas13233-sup-0001" ref-type="supplementary-material">S1</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="cas13233-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Germline alterations identified in wholeâexome sequencing of family members with <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer. (a) Abridged pedigree of familial <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer. Filled symbols, individuals affected by lung cancer (<styled-content style="fixed-case">LC</styled-content>); open symbols, unaffected control individuals (control). Symbols with slashes are deceased individuals. Exomeâsequenced individuals are numbered at the upper left of the symbols. Age shown in years is the age at diagnosis for lung cancer cases and the age at examination for unaffected siblings. Del19 and L858R of <italic><styled-content style="fixed-case">EGFR</styled-content></italic> alterations in lung cancer indicate an inâframe deletion on exon 19 and a point mutation L858R on exon 21, respectively; <styled-content style="fixed-case">ND</styled-content>, not determined. (b) Regional plots of 185 candidate variants in all four patients, but not in the unaffected siblings. The allele frequencies in Japanese individuals (<italic>n</italic> = 1070) are plotted across the human genome. The homozygous (hom) and heterozygous (het) variants are shown with the pathogenic impact predicted as deleterious or benign by the <styled-content style="fixed-case">CADD</styled-content> scores over or below 15, respectively. (c) Details of 14 variants selected as rare (allele frequency &lt;10<sup>â2</sup>) and deleterious (<styled-content style="fixed-case">CADD</styled-content> score &gt;15). <styled-content style="fixed-case">AA</styled-content>, amino acid; Freq. <styled-content style="fixed-case">JPN</styled-content>, allele frequency in Japanese individuals; Freq. <styled-content style="fixed-case">ESP</styled-content>, allele frequency in American individuals of the <styled-content style="fixed-case">NHLBI GO</styled-content> Exome Sequencing Project; <styled-content style="fixed-case">NA</styled-content>, not available. In (a) and (c), <styled-content style="fixed-case">MAF</styled-content> denotes minor allele frequency (&lt;1/2140); the frequency is not specified in the gray area (b), because the variant was not detected in the database.</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="CAS-108-1263-g001"/>
        </fig>
        <p>To clarify the genetic etiology of the familial <italic>EGFR</italic>âmutant lung cancer, we performed exome capture followed by deep sequencing on four affected individuals (subjects 1, 2, 4 and 5) and two unaffected control individuals (subjects 3 and 6). An average of 22 944 exonic variants per individual were noted in the genomic DNA from the peripheral blood of the family members, and an average of 1436 variants were novel according to databases of the dbSNP and the NHLBI GO Exome Sequencing Project (Table <xref rid="cas13233-sup-0001" ref-type="supplementary-material">S2</xref>).</p>
        <p>When comparing the sequenced family members, we found 185 candidate variants that altered the amino acid sequence and were shared by all four lung cancer patients (subjects 1, 2, 4 and 5), but were not observed in the unaffected siblings (subjects 3 and 6); there were 34 homozygous and 151 heterozygous variants; and there were 176 missense, 3 nonsense and 6 insertion and/or deletion (indel) variants (Tables <xref rid="cas13233-sup-0001" ref-type="supplementary-material">S3âS8</xref>). Among these candidates, the causative mutation is expected to be a relatively rare variant in the Japanese general population with a predicted functional consequence. After annotation by both an allele frequency database of 1070 Japanese individuals and a prediction program CADD of pathological impact, 14 heterozygous variants of 185 variants were defined as rare (allele frequency &lt;10<sup>â2</sup>) and deleterious (CADD score &gt; 15); there were 10 missense, 1 nonsense and 3 indel variants (Fig. <xref rid="cas13233-fig-0001" ref-type="fig">1</xref>b,c).</p>
        <p>From the 14 rare and deleterious variants, 4 were excluded as benign variants predicted by another program, polyphenâ2, and 3 (i.e. <italic>DLGAP3</italic>,<italic> SLC25A40</italic> and <italic>MET</italic>) remained under the following criteria: the variant is observed in the Japanese database, but is <italic>de novo</italic> in the NHLBI GO Exome Sequencing Project (ESP) and dbSNP database, given the genetic susceptibility of the Asian population including Japanese to <italic>EGFR</italic>âmutant lung cancer (Fig. <xref rid="cas13233-fig-0001" ref-type="fig">1</xref>c).<xref rid="cas13233-bib-0003" ref-type="ref">3</xref> Notably, of the remaining 3 variants, the p.Asn375Lys substitution of MET, known to be implicated in EGFR signaling, has been observed with the lowest frequency in the Japanese database, suggesting that the <italic>MET</italic> variant could potentially cause <italic>EGFR</italic>âmutant lung cancer.<xref rid="cas13233-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13233-bib-0008" ref-type="ref">8</xref>
</p>
      </sec>
      <sec id="cas13233-sec-0007">
        <title>The altered residue in genetic and protein structures of MET</title>
        <p>MET, a receptor tyrosine kinase for HGF, consists of a disulfideâlinked heterodimer of 50âkDa Î±âchain and 140âkDa transmembrane Î²âchain subunits that are cleaved from a 1390 amino acid precursor form (Fig. <xref rid="cas13233-fig-0002" ref-type="fig">2</xref>a). The altered residue, asparagine at amino acid 375, locates in the semaphorinâlike (Sema) domain that is generally regarded as responsible for binding to HGF and is highly conserved across species, including chimpanzee, dog, cow, mouse, rat and chicken (Fig. <xref rid="cas13233-fig-0002" ref-type="fig">2</xref>b). Close examination of the altered residue in the MET crystal structure revealed that the position is encompassed by a particular section, amino acids 367â426, termed extrusion with a distinctive feature, which is involved in dimerization contacts of MET Î±âchains and Î²âchains as well as HGF binding of the Sema domain (Fig. <xref rid="cas13233-fig-0002" ref-type="fig">2</xref>c).<xref rid="cas13233-bib-0011" ref-type="ref">11</xref> Subsequent Sanger sequencing of the encoding region showed that the blood of affected individuals was heterozygous for the relevant singleânucleotide change (c.1125C&gt;G), while the tumor of subject 5 was homozygous for the variant, indicating somatic loss of heterozygosity (LOH) at this locus (Fig. <xref rid="cas13233-fig-0002" ref-type="fig">2</xref>d). Although the similar LOH was not confirmed in the tumors of other affected individuals (subjects 1, 2, and 4) due to quantitative and/or qualitative insufficiency of the clinical samples, these results support the possibility that the missense variant of <italic>MET</italic> at amino acid 375 represents a pathogenic mutation that disrupts the protein function.</p>
        <fig fig-type="Figure" xml:lang="en" id="cas13233-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Location of the <italic><styled-content style="fixed-case">MET</styled-content></italic> mutation found in familial <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer. (a) Schematic representation of the <styled-content style="fixed-case">MET</styled-content> protein. The transmembrane protein consists of the semaphorinâlike (Sema) domain, the plexinâsemaphorinâintegrin (<styled-content style="fixed-case">PSI</styled-content>) domain, the immunoglobulinâplexinâtranscription factor (<styled-content style="fixed-case">IPT</styled-content>) 1â4 domains, the juxtamembrane (<styled-content style="fixed-case">JM</styled-content>) domain, and the kinase domain. The precursor is cleaved into Î±âchains and Î²âchains, thus yielding the disulfideâlinked heterodimer. The <styled-content style="fixed-case">NP</styled-content>_000236.2 protein was used as a reference for the positions. <styled-content style="fixed-case">AA</styled-content>, amino acid. (b) Protein sequence alignment of <styled-content style="fixed-case">MET</styled-content> (amino acid residues 371â390) in vertebrate species. Altered residues are colored red. The residues corresponding to the missense mutation found in familial <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer are boxed. (c) The 3âD structure of <styled-content style="fixed-case">HGF</styled-content>â<styled-content style="fixed-case">MET</styled-content> complex. The modeling was generated using the Protein Data Bank (<styled-content style="fixed-case">PDB</styled-content>) <styled-content style="fixed-case">ID</styled-content> 1<styled-content style="fixed-case">SHY</styled-content>; grey, <styled-content style="fixed-case">HGF</styled-content> Î²âchain; green, <styled-content style="fixed-case">MET</styled-content> Î±âchain; blue, Sema and <styled-content style="fixed-case">PSI</styled-content> domains of <styled-content style="fixed-case">MET</styled-content> Î²âchain; orange, Asn375 in <styled-content style="fixed-case">MET</styled-content> Î²âchain. (d) Sanger sequencing chromatograms for <italic><styled-content style="fixed-case">MET</styled-content></italic> (amino acid residues 371â380) in blood and tumor cells from the individual affected by familial <italic><styled-content style="fixed-case">EGFR</styled-content></italic>âmutant lung cancer. Blood cells from an unaffected control individual were used as a control.</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="CAS-108-1263-g002"/>
        </fig>
      </sec>
      <sec id="cas13233-sec-0008">
        <title>Hepatocyte growth factorâbinding capacity impaired by the conformational change of the mutant <italic>MET</italic>
</title>
        <p>We carried out 3âD modeling of MET protein to examine whether the missense mutation in <italic>MET</italic> may influence the structure (Fig. <xref rid="cas13233-fig-0003" ref-type="fig">3</xref>a). This modeling showed that the MET p.Asn375Lys (c.1125C&gt;G) mutation is likely to affect helical and loop structures of the extrusion section in the Sema domain.<xref rid="cas13233-bib-0011" ref-type="ref">11</xref> The Asn375 residue in MET forms hydrogen bonds with Arg280 and Asn371, the former of which is disrupted by the alteration of this asparagine residue to lysine. Thus, the p.Asn375Lys mutation is predicted to increase the conformational flexibility of the Sema domain, potentially impairing the HGFâbinding surface and having an effect on the interactions with HGF.</p>
        <fig fig-type="Figure" xml:lang="en" id="cas13233-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Structure and function of wildâtype (Asn375) and mutant (Lys375) <styled-content style="fixed-case">MET</styled-content> ectodomains. (a) Ribbon representation of the <styled-content style="fixed-case">MET</styled-content> ectodomains. Asn375 and Lys375 are shown with the surrounding residues by ballâandâstick models. Lines represent hydrogen bonds with the distances; gray, carbon; red, oxygen; blue, nitrogen. (b) <styled-content style="fixed-case">HGF</styled-content>âbinding capacity of the <styled-content style="fixed-case">MET</styled-content> ectodomains. <styled-content style="fixed-case">MET</styled-content>âFc fusion protein was immobilized to <styled-content style="fixed-case">ELISA</styled-content> plates and incubated with increasing concentrations of recombinant human <styled-content style="fixed-case">HGF</styled-content> protein. The bound <styled-content style="fixed-case">HGF</styled-content> was detected by antiâ<styled-content style="fixed-case">HGF</styled-content> Ab and colorimetrically quantified as <styled-content style="fixed-case">MET</styled-content>â<styled-content style="fixed-case">HGF</styled-content> binding affinity by the absorbance value at <styled-content style="fixed-case">OD</styled-content>
<sub>450</sub>. (c) Binding specificity of the <styled-content style="fixed-case">MET</styled-content> ectodomains to <styled-content style="fixed-case">HGF</styled-content>. The study was identical to that described in (b), except that the immobilized <styled-content style="fixed-case">MET</styled-content>âFc protein was pretreated with antiâ<styled-content style="fixed-case">MET</styled-content> antagonistic Ab or isotype control Ab before incubation with 40 ng/<styled-content style="fixed-case">mL HGF</styled-content>. (d) Coprecipitation analysis of the <styled-content style="fixed-case">MET</styled-content> ectodomains with <styled-content style="fixed-case">HGF</styled-content>. Recombinant human <styled-content style="fixed-case">HGF</styled-content> protein was coprecipitated with <styled-content style="fixed-case">MET</styled-content>âFc fusion protein immobilized on protein GâSepharose beads. The precipitates were resolved by <styled-content style="fixed-case">SDS</styled-content>â<styled-content style="fixed-case">PAGE</styled-content> and then visualized by immunoblotting with antiâ<styled-content style="fixed-case">HGF</styled-content> or antiâ<styled-content style="fixed-case">MET</styled-content> Ab. For (b) and (c), data are presented as the mean Â± standard error of <italic>n</italic> = 4 (b) or <italic>n</italic> = 3 (c) per group.</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="CAS-108-1263-g003"/>
        </fig>
        <p>Accordingly, we sought to investigate the impact of the identified <italic>MET</italic> mutation on the binding affinity to HGF by using recombinant METâFc fusion proteins, in which wildâtype or mutant MET ectodomains were fused to the Fc region of human IgG1 (Fig. <xref rid="cas13233-fig-0003" ref-type="fig">3</xref>bâd). Based on the ELISA assay of recombinant HGF protein bound to the METâFc fusion protein, the amount of HGF bound to wildâtype MET, but not to p.Asn375Lysâmutant MET, sharply increased in a manner that was dependent on the concentration of the applied HGF (wildâtype <italic>vs</italic> mutant MET: 1.25â20 ng/mL, <italic>P</italic> &gt; 0.4; 40â80 ng/mL, <italic>P</italic> &lt; 0001; Fig. <xref rid="cas13233-fig-0003" ref-type="fig">3</xref>b). Evidence for the specificity of the observed binding was provided by the finding that pretreatment with antiâMET antagonistic antibody significantly neutralized the HGF binding of wildâtype METâFc fusion protein, but not p.Asn375Lysâmutant METâFc fusion protein (antiâMET <italic>vs</italic> control antibodies: wildâtype MET, <italic>P</italic> &lt; 0.05; mutant MET, <italic>P</italic> &gt; 0.2; Fig. <xref rid="cas13233-fig-0003" ref-type="fig">3</xref>c). Consistent with these ELISA data, coprecipitation of the HGF protein followed by western blot analysis displayed a markedly decreased level of HGF bound to p.Asn375Lysâmutant METâFc fusion protein as compared to wildâtype METâFc fusion protein (Fig. <xref rid="cas13233-fig-0003" ref-type="fig">3</xref>d). Taken together, these results demonstrated that the HGFâbinding capacity of the MET ectodomain was abrogated in the p.Asn375Lys alteration of MET.</p>
      </sec>
      <sec id="cas13233-sec-0009">
        <title>Biological function damaged by the missense change of <italic>MET</italic>
</title>
        <p>To reveal the biological impact of the identified mutation in <italic>MET</italic>, we retrovirally transduced H1299 lung cancer cells to stably express wildâtype or p.Asn375Lysâmutant MET (Fig. <xref rid="cas13233-fig-0004" ref-type="fig">4</xref>). Both H1299 transductants with the wildâtype and mutant <italic>MET</italic> cDNA expressed comparable protein levels of MET, whereas the control transductant with no transgene (i.e. null vector) did not express MET at a detectable protein level (Fig. <xref rid="cas13233-fig-0004" ref-type="fig">4</xref>a). Despite these MET expression patterns, the H1299 transductant expressing wildâtype MET, but not the p.Asn375Lysâmutant MET, showed increased cell proliferation as early as day 2 of the HGFâsupplemented culture and until at least day 4, as compared with the control null transductant (wildâtype versus mutant MET: <italic>P</italic> &lt; 0.05 on day 2, <italic>P</italic> &lt; 0.0001 on day 4; wildâtype MET versus null: <italic>P</italic> &lt; 0.05 on day 2, <italic>P</italic> &lt; 0.0005 on day 4; mutant MET versus null: <italic>P</italic> &gt; 0.9 on day 2, <italic>P</italic> &gt; 0.8 on day 4; Fig. <xref rid="cas13233-fig-0004" ref-type="fig">4</xref>b). The levels of <italic>in vitro</italic> colony formation, an indicator of the clonogenic potential, were also significantly higher in the H1299 transductant with wildâtype MET than in that with the p.Asn375Lysâmutant MET, which exhibited similar levels to those of the control null transductant (wildâtype versus mutant MET, <italic>P</italic> &lt; 0.005; wildâtype MET versus null, <italic>P</italic> &lt; 0.005; mutant MET versus null, <italic>P</italic> &gt; 0.4; Fig. <xref rid="cas13233-fig-0004" ref-type="fig">4</xref>c). As determined by the gap closure of the scratched cell monolayer in the HGFâsupplemented culture, the cell motility was significantly augmented upon transduction with wildâtype MET, but remained unchanged or was only mildly reduced upon transduction with p.Asn375Lysâmutant MET compared to transduction with no transgene (wildâtype versus mutant MET, <italic>P</italic> &lt; 0.0005; wildâtype MET <italic>vs</italic> null, <italic>P</italic> &lt; 0.005; mutant MET <italic>vs</italic> null, <italic>P</italic> &gt; 0.4; Fig. <xref rid="cas13233-fig-0004" ref-type="fig">4</xref>d). These observations supported the premise that the p.Asn375Lys alteration mediates the functional damage to MET and could be a potential mechanism in the development of <italic>EGFR</italic>âmutant lung tumors.</p>
        <fig fig-type="Figure" xml:lang="en" id="cas13233-fig-0004" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>
<italic>In vitro</italic> properties of H1299 lung cancer cells retrovirally transduced to stably express wildâtype (Asn375) and mutant (Lys375) <styled-content style="fixed-case">MET</styled-content>. (a) <styled-content style="fixed-case">MET</styled-content> expression analysis by western blot. The cell lysates were prepared from transduced H1299 cells and immunoblotted for <styled-content style="fixed-case">MET</styled-content> and Î²âactin (loading control). (b) Proliferative capacity. Transduced H1299 cells were starved overnight for serum, and then cultured in lowâserum media supplemented with 5 ng/<styled-content style="fixed-case">mL</styled-content> recombinant human <styled-content style="fixed-case">HGF</styled-content> protein. After 2 and 4 days of the culture, the number of viable cells was colorimetrically assessed by the absorbance value at <styled-content style="fixed-case">OD</styled-content>
<sub>490</sub>. (c) Clonogenic capacity. The study was similar to that in (b), but, 2 weeks after the culture, the colonies were stained with crystal violet for counting the number in each plate. (d) Motile capacity. The study was similar to that in (b), but the serumâstarved cells were scraped (day 0) and cultured for 2 days. The closed wound area on day 2 was quantified as the percentage of the open wound area on day 0. Scale bar, 200 Î¼m. For all figure parts, controls included H1299 cells transduced with control null vector that is identical to the <styled-content style="fixed-case">MET</styled-content>âexpressing retrovirus vectors but contains no transgene. Data are presented as the mean Â± standard error of <italic>n</italic> = 3 (b,c) or <italic>n</italic> = 6 (d) per group, except for (a).</p>
          </caption>
          <graphic id="nlm-graphic-9" xlink:href="CAS-108-1263-g004"/>
        </fig>
      </sec>
      <sec id="cas13233-sec-0010">
        <title>Defective tumorigenicity and the vital signaling downstream of the mutant MET</title>
        <p>Finally, we investigated how the stable expression of wildâtype or mutant MET in lung cancer cells affects the tumorigenic potential and the relevant molecular pathway of MET (Fig. <xref rid="cas13233-fig-0005" ref-type="fig">5</xref>). Consistent with our <italic>in vitro</italic> results, stable transduction of H1299 lung cancer cells with wildâtype MET significantly increased the tumor growth on the flanks of implanted mice at time points from day 44 to day 54, as compared to that with the p.Asn375Lysâmutant MET (as measured by tumor volume, <italic>P</italic> &lt; 0.005, Fig. <xref rid="cas13233-fig-0005" ref-type="fig">5</xref>a). At the end of the experiment on day 54, mice implanted with H1299 cells expressing wildâtype MET had a greater tumor burden compared to mice implanted with H1299 cells expressing p.Asn375Lysâmutant MET (photographic inset, Fig. <xref rid="cas13233-fig-0005" ref-type="fig">5</xref>a; 2.7âfold increase, as measured by tumor weight, <italic>P</italic> &lt; 0.005, Fig. <xref rid="cas13233-fig-0005" ref-type="fig">5</xref>b). We next verified that stimulation with recombinant HGF protein enhanced the amount of phosphorylated MET (PâMET), which was greater in H1299 cells expressing wildâtype MET than in those expressing p.Asn375Lysâmutant MET in either condition with or without the HGF stimulation (Fig. <xref rid="cas13233-fig-0005" ref-type="fig">5</xref>c). Recently, among complex signaling events that follow the MET ligation by HGF, the functional crosstalk of MET with ERBB3âPI3KâAKT signaling has been shown to be a crucial mechanism in the progression of lung cancer.<xref rid="cas13233-bib-0009" ref-type="ref">9</xref>, <xref rid="cas13233-bib-0012" ref-type="ref">12</xref> To determine whether the ERBB3âPI3KâAKT pathway is influenced by the identified mutation of MET, we analyzed the phosphorylation of ERBB3 and p70 S6 kinase (a downstream mediator of AKT). H1299 cells expressing wildâtype MET augmented the phosphorylation of both ERBB3 and p70 S6 kinase upon HGF stimulation, whereas H1299 cells expressing p.Asn375Lysâmutant MET were crippled not only for the phosphorylation but also for the protein expression of both pathway members with compromised reactivity in response to the HGF stimulation (Fig. <xref rid="cas13233-fig-0005" ref-type="fig">5</xref>c). Moreover, in the published data, <italic>EGFR</italic>âmutant lung adenocarcinomas were less likely to express <italic>MET</italic> mRNA at a markedly increased level than those negative for sensitizing <italic>EGFR</italic> mutations (4 <italic>vs</italic> 16%, Table <xref rid="cas13233-sup-0001" ref-type="supplementary-material">S9</xref>).<xref rid="cas13233-bib-0013" ref-type="ref">13</xref>, <xref rid="cas13233-bib-0014" ref-type="ref">14</xref> These results reinforced our notion that the missense mutation abolishes the ability of MET to activate the ERBB3âPI3KâAKT pathway associated with tumorigenicity, thereby prompting lung cells to acquire constitutively activating mutations of <italic>EGFR</italic> (also known as <italic>ERBB1</italic>) for replenishment of the disrupted AKT activation.</p>
        <fig fig-type="Figure" xml:lang="en" id="cas13233-fig-0005" orientation="portrait" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Tumor growth and <styled-content style="fixed-case">MET</styled-content> signaling of H1299 lung cancer cells retrovirally transduced to stably express wildâtype (Asn375) and mutant (Lys375) <styled-content style="fixed-case">MET</styled-content>. (a) Tumor volume. Transduced H1299 cells (2.5 Ã 10<sup>6</sup>) were injected subcutaneously in the right flank of female <styled-content style="fixed-case">BALB</styled-content>/c nu/nu mice on day 0. On and after day 26, the volume of each tumor was assessed two or three times weekly. The tumors on day 54 are shown in the photographic inset; scale bar, 10 mm. (b) Tumor weight. The weight of the tumors shown in the inset of (a) was assessed. (c) Altered downstream signaling. Transduced H1299 cells were treated with 50 ng/<styled-content style="fixed-case">mL</styled-content> recombinant human <styled-content style="fixed-case">HGF</styled-content> protein (<styled-content style="fixed-case">rHGF</styled-content>) or vehicle control for 15 min and lysed. The cell lysates were resolved by <styled-content style="fixed-case">SDS</styled-content>âpolyacrylamide gel electrophoresis and then visualized by immunoblotting for phosphoâ<styled-content style="fixed-case">MET</styled-content> (Pâ<styled-content style="fixed-case">MET</styled-content>), phosphoâ<styled-content style="fixed-case">ERBB</styled-content>3 (Pâ<styled-content style="fixed-case">ERBB</styled-content>3), and phosphoâp70 S6 kinase (Pâp70S6). Total <styled-content style="fixed-case">MET</styled-content>,<styled-content style="fixed-case"> ERBB</styled-content>3 and p70S6 in the lysates were used as loading controls, respectively. Data are presented as the mean Â± standard error of <italic>n</italic> = 3 per group, except for (c).</p>
          </caption>
          <graphic id="nlm-graphic-11" xlink:href="CAS-108-1263-g005"/>
        </fig>
      </sec>
    </sec>
    <sec id="cas13233-sec-0011">
      <title>Discussion</title>
      <p>To determine the genetic factors underlying <italic>EGFR</italic>âmutant lung cancer, we focused on familial cases and performed exome sequencing on their germline DNA. We then identified the heterozygous c.1125C&gt;G (p.Asn375Lys) variant in <italic>MET</italic>, which encodes a receptor tyrosine kinase that could mutually complement EGFR to activate the downstream PI3KâAKT signaling in lung cancer. The missense mutation affects a highly conserved amino acid residue in the extracellular HGFâbinding Sema domain, thus damaging the ligation by HGF and the subsequent MET activation that leads to cellular responses such as proliferation, clonogenicity, motility and tumorigenicity. Moreover, the somatic loss of heterozygosity for the <italic>MET</italic> mutation bolsters our view that the heterozygous inactivating mutation mediates an oncogenic stress to <italic>EGFR</italic>âmutant (i.e. EGFRâaddicted) lung cancers through a haploinsufficiency that reduces the amount of wildâtype MET protein.</p>
      <p>Adenocarcinoma is the most common lung cancer subtype, representing approximately 40% of all lung cancers, with squamous cell lung cancer constituting 20% of these.<xref rid="cas13233-bib-0001" ref-type="ref">1</xref> Relative to adenocarcinoma, squamous cell lung carcinoma has been decreasing, probably due to the stronger epidemiological association with cigarette smoking.<xref rid="cas13233-bib-0002" ref-type="ref">2</xref> Meanwhile, the clinical relevance of lung adenocarcinoma has been strengthened not only by the increasing number of cases but also by the genomic diversity.<xref rid="cas13233-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13233-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13233-bib-0007" ref-type="ref">7</xref>, <xref rid="cas13233-bib-0008" ref-type="ref">8</xref> Recent molecular profiling studies have revealed that, according to cigaretteâsmoking history, distinct genetic abnormalities are found within lung adenocarcinomas as driver mutations in a mutually exclusive pattern; the <italic>KRAS</italic> mutations are more frequently detected in patients with a history of smoking, whereas the <italic>EGFR</italic> mutations and the <italic>EML4</italic>â<italic>ALK</italic> rearrangements are more common in light or neverâsmokers.<xref rid="cas13233-bib-0005" ref-type="ref">5</xref> Notably, EGFR and ALK alterations are recognized to be of great therapeutic significance as predictive biomarkers for the response to tyrosine kinase inhibitors against EGFR and ALK, respectively.<xref rid="cas13233-bib-0001" ref-type="ref">1</xref>, <xref rid="cas13233-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13233-bib-0007" ref-type="ref">7</xref>, <xref rid="cas13233-bib-0008" ref-type="ref">8</xref>
</p>
      <p>Besides a robust association with nonsmoking status, Asian ethnicity was also shown to be associated with an increased likelihood of the activating alterations in the tyrosine kinase of EGFR, suggesting that lung adenocarcinomas positive for <italic>EGFR</italic> mutations have a genetic component to their etiology.<xref rid="cas13233-bib-0003" ref-type="ref">3</xref>, <xref rid="cas13233-bib-0005" ref-type="ref">5</xref> In this context, genomeâwide association studies proposed several chromosomal regions that might be susceptible to lung cancer in nonâsmokers, including chromosomes 3q28, 5p15.33 (telomerase reverse transcriptase, <italic>TERT</italic>), 6p21.32, 6q22.2, 10q25.2, 13q31.3 (glypican 5, <italic>GPC5</italic>), 15q25, 17q24.3 and 18p11.22.<xref rid="cas13233-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13233-bib-0015" ref-type="ref">15</xref>, <xref rid="cas13233-bib-0016" ref-type="ref">16</xref> Other epidemiologic studies demonstrated that variant alleles of several genes are associated with increased susceptibility to lung cancer, such as an <italic>EGFR</italic> germline mutation, and polymorphisms in the cytochrome p450 enzyme genes, DNA mismatch repair genes, and glutathioneâSâtransferase genes.<xref rid="cas13233-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13233-bib-0015" ref-type="ref">15</xref> However, because the results of these association studies have been inconsistent, the oncogenic mechanisms that enable <italic>EGFR</italic>âmutant adenocarcinomas to develop have not been elucidated.</p>
      <p>We identified a missense mutation at <sup>375</sup>asparagine to lysine (i.e. p.Asn375Lys) within the extracellular Sema domain of the <italic>MET</italic> protoâoncogene in lung adenocarcinoma patients. In the screening process of the candidate variants for the causative mutation of the familial <italic>EGFR</italic>âmutant lung cancer, we excluded 7 variants owing to registration in the dbSNP database or nonâregistration in the Japanese database. Although we could not exclude a possible etiologic significance of these variants without further functional studies, the MET engagement is known to have broad implications for cancer biology, including cellular proliferation, cell survival, invasion, cell motility, metastasis and angiogenesis.<xref rid="cas13233-bib-0012" ref-type="ref">12</xref> This knowledge has fostered a systematic analysis of the complete exons of the <italic>MET</italic> gene for a number of solid tumors, and uncovered the frequent occurrence of <italic>MET</italic> mutations in the Sema domain, especially for lung cancer.<xref rid="cas13233-bib-0017" ref-type="ref">17</xref> The Sema domain is crucial for receptor activation and dimerization, providing a specific binding site for HGF.<xref rid="cas13233-bib-0017" ref-type="ref">17</xref>, <xref rid="cas13233-bib-0018" ref-type="ref">18</xref> Within the Sema domain, <sup>375</sup>asparagine has been recognized as a hot spot of cancerâassociated <italic>MET</italic> mutations, and the missense germline change to serine (i.e. p.Asn375Ser) is common in smokers with squamous cell lung carcinoma, but not in neverâsmokers with lung adenocarcinoma.<xref rid="cas13233-bib-0017" ref-type="ref">17</xref> Unlike p.Asn375Ser, we identified the p.Asn375Lys germline mutation of MET in neverâsmokers with familial <italic>EGFR</italic>âmutant lung adenocarcinoma. Our finding and the findings of others suggest that lung adenocarcinoma and squamous cell lung carcinoma emerge in neverâsmokers and everâsmokers, respectively, based on distinct genetic abnormalities.<xref rid="cas13233-bib-0002" ref-type="ref">2</xref>, <xref rid="cas13233-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13233-bib-0007" ref-type="ref">7</xref>, <xref rid="cas13233-bib-0008" ref-type="ref">8</xref>
</p>
      <p>Of note, somatic mutations in the <italic>EGFR</italic> gene have been identified as driver mutations underlying the oncogenic addiction of lung adenocarcinomas in neverâsmokers.<xref rid="cas13233-bib-0005" ref-type="ref">5</xref> Analyses of the signal transduction downstream of the activating <italic>EGFR</italic> mutations revealed the particular efficacy of the EGFRâERBB3 heterodimer to stimulate the PI3KâAKT pathway.<xref rid="cas13233-bib-0008" ref-type="ref">8</xref> Further work on the tumor resistance to EGFRâtargeted therapy has shown that <italic>MET</italic> amplification undergoes a kinase switch under EGFR blockade by driving ERBB3âdependent activation of the PI3KâAKT signaling.<xref rid="cas13233-bib-0019" ref-type="ref">19</xref> Conversely, activation of EGFRâERBB3 signal transduction has been shown to mediate resistance to MET inhibition.<xref rid="cas13233-bib-0020" ref-type="ref">20</xref> These studies indicate that EGFR and MET mutually compensate for activating the PI3KâAKT pathway via interaction with ERBB3. Our study highlights the importance of the compensatory signals in oncogenesis by identifying an inactivating <italic>MET</italic> germline mutation that theoretically enhances the signaling dependence on the EGFRâERBB3âPI3K axis as the oncogenic potential of familial <italic>EGFR</italic>âmutant lung adenocarcinoma.</p>
    </sec>
    <sec id="cas13233-sec-0013">
      <title>Disclosure Statement</title>
      <p>The authors declare no conflict of interest related to this work.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data" id="cas13233-sup-0001">
        <caption>
          <p>
<bold>Doc. S1.</bold> Additional detail on the methods.</p>
          <p>
<bold>Fig. S1.</bold> Chest CT and brain MRI of subject 1 (an 80âyearâold woman).</p>
          <p>
<bold>Table S1.</bold> Sequencing read information and exome coverage statistics for each sample.</p>
          <p>
<bold>Table S2.</bold> Exonic variants called in genomic DNA from peripheral blood.</p>
          <p>
<bold>Table S3.</bold> Chromosome 1â5: candidate variants identified in all four patients, but not in the unaffected siblings.</p>
          <p>
<bold>Table S4.</bold> Chromosome 6: candidate variants identified in all four patients, but not in the unaffected siblings.</p>
          <p>
<bold>Table S5.</bold> Chromosome 7: candidate variants identified in all four patients, but not in the unaffected siblings.</p>
          <p>
<bold>Table S6.</bold> Chromosomes 9â15: candidate variants identified in all four patients, but not in the unaffected siblings.</p>
          <p>
<bold>Table S7.</bold> Chromosomes 16 and 17: candidate variants identified in all four patients, but not in the unaffected siblings.</p>
          <p>
<bold>Table S8.</bold> Chromosomes 18âX: candidate variants identified in all four patients, but not in the unaffected siblings.</p>
          <p>
<bold>Table S9.</bold> Sensitizing EGFR mutations and the levels of MET expression of lung adenocarcinomas among 230 cases.</p>
        </caption>
        <media xlink:href="CAS-108-1263-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="cas13233-sec-0012">
      <title>Acknowledgments</title>
      <p>We thank M. Takahashi, A. Santoso, M. Kanehira, R. Funayama, M. Tsuda, M. Kikuchi, M. Nakagawa and K. Kuroda for their technical assistance, and B. Bell for reading the manuscript. We also acknowledge the technical support of the Biomedical Research Core of Tohoku University Graduate School of Medicine. This work was supported, in part, by GrantsâinâAid for Scientific Research and the Project for Development of Innovative Research on Cancer Therapeutics from the Ministry of Education, Culture, Sports, Science and Technology (Tokyo, Japan), the Core Research for Evolutional Science and Technology Program, the Adaptable and Seamless Technology Transfer Program from the Japan Science and Technology Agency (Tokyo, Japan), and the Urgent Research Grant Program from the Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan).</p>
    </ack>
    <ref-list content-type="cited-references" id="cas13233-bibl-0001">
      <title>References</title>
      <ref id="cas13233-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0001">
<string-name>
<surname>Cagle</surname>
<given-names>PT</given-names>
</string-name>, <string-name>
<surname>Allen</surname>
<given-names>TC</given-names>
</string-name>. <article-title>Lung cancer genotypeâbased therapy and predictive biomarkers: present and future</article-title>. <source>Arch Pathol Lab Med</source>
<year>2012</year>; <volume>136</volume>: <fpage>1482</fpage>â<lpage>91</lpage>.<pub-id pub-id-type="pmid">23194040</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0002">
<string-name>
<surname>de Groot</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Munden</surname>
<given-names>RF</given-names>
</string-name>. <article-title>Lung cancer epidemiology, risk factors, and prevention</article-title>. <source>Radiol Clin North Am</source>
<year>2012</year>; <volume>50</volume>: <fpage>863</fpage>â<lpage>76</lpage>.<pub-id pub-id-type="pmid">22974775</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0003">
<string-name>
<surname>NanaâSinkam</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Powell</surname>
<given-names>CA</given-names>
</string-name>. <article-title>Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidenceâbased clinical practice guidelines</article-title>. <source>Chest</source>
<year>2013</year>; <volume>143</volume>: <fpage>e30S</fpage>â<lpage>9S</lpage>.<pub-id pub-id-type="pmid">23649444</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0004">
<string-name>
<surname>Yokota</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shiraishi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kohno</surname>
<given-names>T</given-names>
</string-name>. <article-title>Genetic basis for susceptibility to lung cancer: recent progress and future directions</article-title>. <source>Adv Cancer Res</source>
<year>2010</year>; <volume>109</volume>: <fpage>51</fpage>â<lpage>72</lpage>.<pub-id pub-id-type="pmid">21070914</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0005">
<string-name>
<surname>Couraud</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Zalcman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Milleron</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Morin</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Souquet</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Lung cancer in never smokersâA review</article-title>. <source>Eur J Cancer</source>
<year>2012</year>; <volume>48</volume>: <fpage>1299</fpage>â<lpage>311</lpage>.<pub-id pub-id-type="pmid">22464348</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0006">
<string-name>
<surname>Roskoski</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>ErbB/HER proteinâtyrosine kinases: structures and small molecule inhibitors</article-title>. <source>Pharmacol Res</source>
<year>2014</year>; <volume>87</volume>: <fpage>42</fpage>â<lpage>59</lpage>.<pub-id pub-id-type="pmid">24928736</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0007">
<string-name>
<surname>Swanton</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Govindan</surname>
<given-names>R</given-names>
</string-name>. <article-title>Clinical implications of genomic discoveries in lung cancer</article-title>. <source>N Engl J Med</source>
<year>2016</year>; <volume>374</volume>: <fpage>1864</fpage>â<lpage>73</lpage>.<pub-id pub-id-type="pmid">27168435</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0008">
<string-name>
<surname>Buettner</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wolf</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>RK</given-names>
</string-name>. <article-title>Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment</article-title>. <source>J Clin Oncol</source>
<year>2013</year>; <volume>31</volume>: <fpage>1858</fpage>â<lpage>65</lpage>.<pub-id pub-id-type="pmid">23589544</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0009">
<string-name>
<surname>Engelman</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Zejnullahu</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mitsudomi</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic>
<article-title>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling</article-title>. <source>Science</source>
<year>2007</year>; <volume>316</volume>: <fpage>1039</fpage>â<lpage>43</lpage>.<pub-id pub-id-type="pmid">17463250</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0010">
<string-name>
<surname>Sakakibara</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Saijo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukuhara</surname>
<given-names>T</given-names>
</string-name>
<italic>et al</italic>
<article-title>Adenocarcinoma with epidermal growth factor receptor gene mutations in three siblings</article-title>. <source>J Thorac Oncol</source>
<year>2008</year>; <volume>3</volume>: <fpage>311</fpage>â<lpage>3</lpage>.<pub-id pub-id-type="pmid">18317075</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0011">
<string-name>
<surname>Niemann</surname>
<given-names>HH</given-names>
</string-name>. <article-title>Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1</article-title>. <source>Biochim Biophys Acta</source>
<year>2013</year>; <volume>1834</volume>: <fpage>2195</fpage>â<lpage>204</lpage>.<pub-id pub-id-type="pmid">23123275</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0012">
<string-name>
<surname>Gherardi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Birchmeier</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Birchmeier</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vande Woude</surname>
<given-names>G</given-names>
</string-name>. <article-title>Targeting MET in cancer: rationale and progress</article-title>. <source>Nat Rev Cancer</source>
<year>2012</year>; <volume>12</volume>: <fpage>89</fpage>â<lpage>103</lpage>.<pub-id pub-id-type="pmid">22270953</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0013">
<collab collab-type="authors">Cancer Genome Atlas Research Network</collab>
. <article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title>. <source>Nature</source>
<year>2014</year>; <volume>511</volume>: <fpage>543</fpage>â<lpage>50</lpage>.<pub-id pub-id-type="pmid">25079552</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0014">
<string-name>
<surname>Cerami</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dogrusoz</surname>
<given-names>U</given-names>
</string-name>
<italic>et al</italic>
<article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>. <source>Cancer Discov</source>
<year>2012</year>; <volume>2</volume>: <fpage>401</fpage>â<lpage>4</lpage>.<pub-id pub-id-type="pmid">22588877</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0015">
<string-name>
<surname>Marshall</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Christiani</surname>
<given-names>DC</given-names>
</string-name>. <article-title>Genetic susceptibility to lung cancerâLight at the end of the tunnel?</article-title>
<source>Carcinogenesis</source>
<year>2013</year>; <volume>34</volume>: <fpage>487</fpage>â<lpage>502</lpage>.<pub-id pub-id-type="pmid">23349013</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0016">
<string-name>
<surname>Shiraishi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kunitoh</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Daigo</surname>
<given-names>Y</given-names>
</string-name>
<italic>et al</italic>
<article-title>A genomeâwide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population</article-title>. <source>Nat Genet</source>
<year>2012</year>; <volume>44</volume>: <fpage>900</fpage>â<lpage>3</lpage>.<pub-id pub-id-type="pmid">22797724</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0017">
<string-name>
<surname>Sattler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Reddy</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Hasina</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gangadhar</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Salgia</surname>
<given-names>R</given-names>
</string-name>. <article-title>The role of the câMet pathway in lung cancer and the potential for targeted therapy</article-title>. <source>Ther Adv Med Oncol</source>
<year>2011</year>; <volume>3</volume>: <fpage>171</fpage>â<lpage>84</lpage>.<pub-id pub-id-type="pmid">21904579</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0018">
<string-name>
<surname>KongâBeltran</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stamos</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wickramasinghe</surname>
<given-names>D</given-names>
</string-name>. <article-title>The Sema domain of Met is necessary for receptor dimerization and activation</article-title>. <source>Cancer Cell</source>
<year>2004</year>; <volume>6</volume>: <fpage>75</fpage>â<lpage>84</lpage>.<pub-id pub-id-type="pmid">15261143</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0019">
<string-name>
<surname>Sadiq</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Salgia</surname>
<given-names>R</given-names>
</string-name>. <article-title>MET as a possible target for nonâsmallâcell lung cancer</article-title>. <source>J Clin Oncol</source>
<year>2013</year>; <volume>31</volume>: <fpage>1089</fpage>â<lpage>96</lpage>.<pub-id pub-id-type="pmid">23401458</pub-id></mixed-citation>
      </ref>
      <ref id="cas13233-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="cas13233-cit-0020">
<string-name>
<surname>Corso</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ghiso</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Cepero</surname>
<given-names>V</given-names>
</string-name>
<italic>et al</italic>
<article-title>Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition</article-title>. <source>Mol Cancer</source>
<year>2010</year>; <volume>9</volume>: <fpage>121</fpage>.<pub-id pub-id-type="pmid">20500904</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>